newsfilter
← Latest News
GlobeNewswire·

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

BLSM
  • BlossomHill Therapeutics will present updated data on BH-30643 anti-tumor activity in patients with secondary EGFR resistance mutations like C797S at the 2026 World Conference on Lung Cancer.
  • The mini-oral presentation is scheduled for September 15, 2026, in Seoul, South Korea, as part of Session MO12.
  • BH-30643 received Fast Track designation from the FDA for treating C797S-positive EGFR-mutant NSCLC, a setting with no approved oral targeted therapies.
  • The drug is an investigational, non-covalent, macrocyclic, brain-active, mutant-selective OMNI-EGFR™ inhibitor evaluated in the global Phase 1/2 SOLARA trial.
  • Preclinical studies showed BH-30643 has potent activity across diverse EGFR mutation categories while maintaining selectivity over wild-type EGFR.
  • The SOLARA trial spans over 40 sites in 10 countries \& includes dose expansion cohorts for both TKI-pretreated \& TKI-naive patients, including a specific C797S resistance cohort.
  • Dr. Hidehito Horinouchi from the National Cancer Center Hospital in Tokyo will present the data titled "Anti-Tumor Activity of BH-30643, a Novel Macrocyclic EGFR TKI, in Patients With Secondary EGFR Resistance Mutations."
  • BlossomHill Therapeutics is also developing BH-501284, a preclinical pan-KRAS Switch II inhibitor, \& BH-30236, a macrocyclic CLK inhibitor for AML \& MDS.
  • The company is headquartered in San Diego, California, \& was founded \& led by J. Jean Cui, Ph.D., a veteran with three FDA-approved oncology drugs.